openPR Logo
Press release

Primary Ciliary Dyskinesia Market Insights: Epidemiology Trends, Pipeline Advances, and Forecast Growth to 2034 | DelveInsight

08-21-2025 01:12 AM CET | Business, Economy, Finances, Banking & Insurance

Press release from: ABNewswire

Primary Ciliary Dyskinesia Market Insight, Epidemiology and Market Forecast

Primary Ciliary Dyskinesia Market Insight, Epidemiology and Market Forecast

DelveInsight's latest report on Primary Ciliary Dyskinesia (PCD) forecasted significant growth in the PCD market, driven by improved diagnostic methods, a rising prevalence of the disease, and the expected entry of novel therapies such as P-1037 IS/VX-371 (PARION SCIENCES), RCT1100 (RECODE THERAPEUTICS), ETH 42 (ETHRIS GmbH), CIL-05 (CILA THERAPEUTICS), and others.
DelveInsight's latest "Primary Ciliary Dyskinesia Market Insight, Epidemiology and Market Forecast [https://www.delveinsight.com/report-store/primary-ciliary-dyskinesia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]" report combines robust epidemiological data with market trends, competitive landscape analysis, and patient journey assessments. The report forecasts that the market size for Primary Ciliary Dyskinesia (PCD) in 7MM, which includes the United States, EU4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan, is expected to increase from approximately USD 101 million in 2023 over the next 10 years. Among the 7MM, the US market is expected to rise at a significant CAGR from approximately USD 36 million in 2023. This growth is attributed to increased awareness, improved screening and diagnosis rates, a rising prevalence of the disease, and the anticipated introduction of emerging therapies.

Download the Primary Ciliary Dyskinesia Market report to understand which factors are driving the primary ciliary dyskinesia therapeutic market @ Primary Ciliary Dyskinesia Market Trends [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

The report also offers an in-depth epidemiological analysis and forecasts up to 2034, segmented by Primary Ciliary Dyskinesia prevalent cases, Primary Ciliary Dyskinesia diagnosed prevalent cases, age-specific cases, Primary Ciliary Dyskinesia prevalence by pathogenic variants in genes, and Primary Ciliary Dyskinesia prevalent cases by clinical manifestations across the 7MM. According to research conducted by DelveInsight's analysts, the general prevalence of PCD is reported to be between 1 in 11,000 and 1 in 16,000 live births, although the actual prevalence may be higher. In the UK, the prevalence is estimated to be 1 in 7,500, with about 3,000 diagnosed prevalent cases. The US, on the other hand, has nearly 1,800 diagnosed prevalent cases in 2023 out of ~70,000 total diagnosed prevalent cases of PCD in 7MM. It has also been observed that children aged 6 to 20 years account for the highest number of cases, particularly in the United States, and this trend is expected to continue during the forecast period.

Discover evolving trends in the primary ciliary dyskinesia patient pool forecasts @ Primary Ciliary Dyskinesia Epidemiology Analysis [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

DelveInsight's analysis reveals that a decent number of companies are launching clinical trials to investigate new treatment options or improve existing ones. The clinical development pipeline includes drugs such as P-1037 IS/VX-371 (PARION SCIENCES), RCT1100 (RECODE THERAPEUTICS), ETH 42 (ETHRIS GmbH), CIL-05 (CILA THERAPEUTICS), among others.

As there is currently no standard treatment for PCD, the focus remains on managing respiratory symptoms, preventing infections, opening airways, and reducing inflammation through antibiotics, bronchodilators, or anti-inflammatory medications. This emphasises the potential of emerging diagnoses and therapies to revolutionise the treatment landscape for PCD.

Among the anticipated emerging therapies, RCT1100 by ReCode Therapeutics, an inhaled mRNA-based investigational therapy, shows promising results in restoring ciliary function in the lungs, addressing the root cause of PCD rather than merely controlling symptoms. The report provides a detailed analysis of the anticipated uptake rates for the potential PCD drugs expected to launch between 2025 and 2034.

Recent developments, including the FDA's Orphan Drug Designation (ODD) for RCT1100 by ReCode Therapeutics in June 2024, along with significant clinical trial updates for TH 42 (ETHRIS GmbH) and CIL-05 (CILA THERAPEUTICS), emphasise the momentum in the field.

Unlock which primary ciliary dyskinesia emerging drug is expected to capture the largest market share in 7MM by 2034. Visit the Primary Ciliary Dyskinesia Drug Insights [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr].

Although PCD presents significant challenges due to its frequent misidentification as a more common respiratory disorder, potentially leading to an underreporting of its true prevalence and significant delays in treatment, the emergence of improved diagnostic methods and novel therapies is set to broaden treatment options and spur market growth.

Table of Contents

1.

KEY INSIGHTS

2.

REPORT INTRODUCTION

3.

PRIMARY CILIARY DYSKINESIA (PCD) MARKET OVERVIEW AT A GLANCE

4.

METHODOLOGY

5.

EXECUTIVE SUMMARY

6.

KEY EVENTS

7.

DISEASE BACKGROUND AND OVERVIEW

8.

PRIMARY CILIARY DYSKINESIA EPIDEMIOLOGY AND PATIENT POPULATION

9.

PRIMARY CILIARY DYSKINESIA PATIENT JOURNEY

10.

PRIMARY CILIARY DYSKINESIA EMERGING THERAPIES

11.

PRIMARY CILIARY DYSKINESIA MARKETED THERAPIES

12.

KOL VIEWS

13.

SWOT ANALYSIS

14.

PRIMARY CILIARY DYSKINESIA UNMET NEEDS

15.

MARKET ACCESS AND REIMBURSEMENT

16.

APPENDIX

17.

DELVEINSIGHT CAPABILITIES

18.

DISCLAIMER

Related Reports:

Primary Ciliary Dyskinesia (PCD) Pipeline Insight [https://www.delveinsight.com/sample-request/primary-ciliary-dyskinesia-pcd-pipeline-insight?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=xpr]

Primary Ciliary Dyskinesia (PCD) Pipeline Insight report provides comprehensive insights about the pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the PCD companies, including PARION SCIENCES, RECODE THERAPEUTICS, ETHRIS, and CILA THERAPEUTICS.

About DelveInsight

DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.

Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Arpit Anand
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=primary-ciliary-dyskinesia-market-insights-epidemiology-trends-pipeline-advances-and-forecast-growth-to-2034-delveinsight]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.

Permanent link to this press release:

Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Primary Ciliary Dyskinesia Market Insights: Epidemiology Trends, Pipeline Advances, and Forecast Growth to 2034 | DelveInsight here

News-ID: 4152941 • Views:

More Releases from ABNewswire

Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repair Services to Support St. Louis Park Homeowners
Bedrock Restoration - Water Fire Mold Damage Service, Expands Water Damage Repai …
Water Fire Mold Damage Service, a trusted provider of property restoration, has announced expanded service offerings to meet the growing demand for professional water damage solutions in the region. Known for their reliable, customer-focused approach, the company continues to support both homeowners and businesses in recovering from unexpected property damage caused by water, fire, or mold. Responding to a Growing Need for Water Damage Restoration Property owners across Minnesota are increasingly seeking
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Injury Attorneys Representation in Port Jefferson Station
Winkler Kurtz LLP Expands Resources to Handle Increased Demand for Personal Inju …
For individuals searching for personal injury attorneys, the expansion of Winkler Kurtz LLP's team means greater accessibility and reduced wait times for consultations. The firm's deep roots in the Port Jefferson Station community allow them to understand local nuances, such as common accident hotspots and specific regional legal precedents. Port Jefferson Station has seen a notable rise in personal injury cases, driven by factors such as increased traffic congestion, construction activity,
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washing Prevents Long-Term Damage in Millsboro DE
Protecting Property Value: Hose Bros Inc Highlights How Professional Power Washi …
For residents searching for power washing near me, Hose Bros Inc offers accessible and reliable services tailored to the Millsboro community. Their local expertise ensures an understanding of regional challenges, such as the impact of salt air on coastal properties or the tendency for humidity to promote mold growth in shaded areas. This knowledge allows them to customize their approach, selecting appropriate pressure levels and cleaning agents for different surfaces. In
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Prices
Tampa Bay Home Remodeling Costs Guide [2025] Kitchen & Bathroom Renovation Price …
A 2025 cost guide to kitchen, bathroom, and full home remodeling in Tampa Bay, featuring expert insights from Craftline Remodeling on pricing, budgeting, and contractor selection. Market Overview: Understanding Tampa Bay Remodeling Investment Trends Tampa Bay's home remodeling market has experienced significant cost evolution in 2025, with project expenses varying dramatically across South Tampa, Carrollwood, Seminole Heights, Clearwater, St. Petersburg, and Wesley Chapel based on material choices, project scope, and contractor expertise.

All 5 Releases


More Releases for Primary

Direct Primary Care Market
Direct Primary Care Market Worth 80.4 Bn 2031- Exclusive Report by InsightAce Analytic Pvt. Ltd. InsightAce Analytic Pvt. Ltd. announces the release of a market assessment report on the "Direct Primary Care Market"- By Type (Clinical Services, Telehealth Services, Laboratory Services, Consultative Services), Care Setting (Office-Based DPC Practices, Home-Based DPC Practices, Telehealth-Only DPC Practices, Hybrid DPC Practices), End Users (Individuals, Employers, Small Businesses, Large Corporations, Insurance Companies (offering DPC as
Primary Sclerosing Cholangitis Market
Primary Sclerosing Cholangitis (PSC) is a rare, chronic liver disease characterized by inflammation and scarring of the bile ducts, leading to liver damage and, ultimately, liver failure. The disease progresses slowly and often goes unnoticed in its early stages. Although the exact cause of PSC remains unknown, it is commonly associated with other inflammatory bowel diseases, particularly ulcerative colitis. The management of PSC includes symptom control, slowing disease progression, and
Primary Biliary Cholangitis Treatment Market
Primary Biliary Cholangitis Treatment Market Global Primary Biliary Cholangitis Treatment Market Expected to Reach US$ YY Million by 2030, Growing at a CAGR of YY%: Market Insights and Dynamics The Global Primary Biliary Cholangitis Treatment Market, which reached US$ YY billion in 2022, is anticipated to achieve US$ YY million by 2030, exhibiting a robust CAGR of YY% during the forecast period from 2024 to 2031. Primary Biliary Cholangitis (PBC), formerly known as
Primary Healthcare Conference 2023
3rd World Congress on Primary Healthcare and Medicare Summit Mercure Roma West, Viale degli Eroi di Cefalonia, 301, 00128 Rome, Italy Email primaryhealthcare@pulsusgathering.org On behalf of the Conference Organizing Committee, we would like to invite all of you for the "3rd Word Congress on Primary Healthcare and Medicare", which is going to be held in Rome, Italy on September 21-23, 2023. Primary Healthcare 2023 focuses on the basic theme "To Manifest the Multimorbidity
Primary Lithium Battery (Primary Lithium Batteries) Market Key Companies and Ana …
The global lithium primary batteries market size will grow from $2.83 billion in 2022 to $2.9 billion in 2023 at a compound annual growth rate (CAGR) of 2.5% Global " Primary Lithium Battery (Primary Lithium Batteries) Market" 2022 Reports give a Key study on the industry status of the Primary Lithium Battery (Primary Lithium Batteries) Manufacturer with the specific statistics, meaning, definition, SWOT Analysis, expert opinion, and recent development across
Primary Prevention of Cancer
Primary prevention of cancer aims to prevent the disease before it ever occurs. More than 4 in 10 cancers as well as cancer deaths are linked to modifiable risk factors that can be altered as part of primary cancer prevention. The modifiable risk factors for primary prevention include: 1. Cigarette smoking: Smoking causes almost all cases of lung cancer and accounts for 30% of all cancer deaths. Prevention strategy for this risk